Fulvestrant

Drug Profile

Fulvestrant

Alternative Names: Faslodex; ICI 182780; ZD 182780; ZD 9238; ZM 182780

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor Research Institute
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Precocious puberty
  • No development reported Endometrial cancer
  • Discontinued Endometriosis

Most Recent Events

  • 13 Oct 2017 Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Fulvestrant for (Combination therapy, Late-stage disease, Second-line therapy or greater) in European Union
  • 28 Aug 2017 Registered for Breast cancer (First-line therapy, Late-stage disease, Metastatic disease, Monotherapy) in USA (IM)
  • 27 Jul 2017 Launched for Breast cancer (First-line therapy, Late-stage disease, Metastatic disease) in Iceland, Liechtenstein, Norway, European Union (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top